Immunotherapy for Esophageal and Gastric Cancer

Keyphrases

• Esophageal Cancer 100%
• Programmed Death-ligand 1 (PD-L1) 100%
• Gastric Cancer 100%
• Tumor 57%
• Immune Cells 57%
• Gastroesophageal Cancer 42%
• Tumor Cells 28%
• Cell-to-cell 28%
• Microsatellite Instability-high (MSI-H) 28%
• Tumor-immune System 28%
• Solid Tumors 14%
• Placebo 14%
• Response Rate 14%
• Overall Survival 14%
• Clinical Data 14%
• Cancer Cells 14%
• Unselected Patients 14%
• Immunotherapeutics 14%
• Tumor-infiltrating 14%
• Epstein-Barr Virus 14%
• Myeloid Cells 14%
• Esophageal Adenocarcinoma 14%
• Chronic Inflammation 14%
• Immunotherapeutic Strategy 14%
• PD-L2 14%
• Checkpoint Inhibitors 14%
• Checkpoint Inhibition 14%
• Advanced Esophageal Cancer 14%
• Nivolumab 14%
• Heavily Pretreated 14%
• Immune Checkpoint 14%
• Immune Microenvironment 14%
• PD-L1 Inhibitor 14%
• Alternate Strategy 14%
• PD-L1 Downregulation 14%
• Immune Signature 14%
• Invasive Margin 14%
• Somatic mutation Burden 14%

Medicine and Dentistry

• Immunotherapy 100%
• Esophageal Cancer 100%
• Stomach Cancer 100%
• Programmed Death-Ligand 1 100%
• Neoplasm 62%
• Malignant Neoplasm 50%
• Immunocompetent Cell 50%
• Tumor Cell 25%
• Solid Malignant Neoplasm 12%
• Cancer Cell 12%
• Biological Marker 12%
• Somatic Mutation 12%
• Placebo 12%
• Upregulation 12%
• Overall Survival 12%
• Microsatellite Instability 12%
• Esophageal Adenocarcinoma 12%
• Epstein Barr Virus 12%
• Chronic Inflammation 12%
• Myeloid Cell 12%
• Epstein-Barr Virus 12%
• Nivolumab 12%

Immunology and Microbiology

• Immunotherapy 100%
• Programmed Death-Ligand 1 100%
• Immunocompetent Cell 50%
• Tumor Cell 25%
• Epstein Barr Virus 25%
• Cancer Cell 12%
• Overall Survival 12%
• Upregulation 12%
• Myeloid 12%
• Somatic Mutation 12%
• Microsatellite Instability 12%
• Nivolumab 12%